Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence True

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Journal of Oncology|September 18, 2010
Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapyMichael Dattoli, Kent Wallner, Lawrence True, et al.
Cancer Journal (Sudbury, Mass.)|March 16, 2002
I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trialKent Wallner, Gregor Merrick, Lawrence True, et al.
American Journal of Clinical Oncology|June 6, 2008
The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cureNathan Bittner, Kent Wallner, Gregory Merrick, et al.
Urology|February 5, 2008
Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapyL Christine Fang, Michael Dattoli, Al Taira, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2004
The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapyTracy Sherertz, Kent Wallner, Gregory Merrick, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 10, 2005
20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trialKent Wallner, Gregory Merrick, Lawrence True, et al.
Brachytherapy|April 6, 2004
Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapyJacques Corriveau, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|March 26, 2003
The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trialsMaged Ghaly, Kent Wallner, Gregory Merrick, et al.
Genes, Chromosomes & Cancer|August 11, 2019
Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological featuresMaria S Tretiakova, Wenjing Wang, Yu Wu, et al.
The Prostate|June 9, 2016
A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate CancerClaire Murphy, Lawrence True, Funda Vakar-Lopez, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Journal of Oncology|September 18, 2010
Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapyMichael Dattoli, Kent Wallner, Lawrence True, et al.
Cancer Journal (Sudbury, Mass.)|March 16, 2002
I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trialKent Wallner, Gregor Merrick, Lawrence True, et al.
American Journal of Clinical Oncology|June 6, 2008
The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cureNathan Bittner, Kent Wallner, Gregory Merrick, et al.
Urology|February 5, 2008
Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapyL Christine Fang, Michael Dattoli, Al Taira, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2004
The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapyTracy Sherertz, Kent Wallner, Gregory Merrick, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 10, 2005
20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trialKent Wallner, Gregory Merrick, Lawrence True, et al.
Brachytherapy|April 6, 2004
Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapyJacques Corriveau, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|March 26, 2003
The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trialsMaged Ghaly, Kent Wallner, Gregory Merrick, et al.
Genes, Chromosomes & Cancer|August 11, 2019
Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological featuresMaria S Tretiakova, Wenjing Wang, Yu Wu, et al.
The Prostate|June 9, 2016
A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate CancerClaire Murphy, Lawrence True, Funda Vakar-Lopez, et al.
Pageof 6